ZULRESSO now available for some women with postpartum depression before official launch
NCT ID NCT03924492
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This program offers ZULRESSO (brexanolone) injection to a limited number of adult women with postpartum depression before the drug is widely available. Healthcare providers must apply for each patient, and eligibility is based on medical need and safety criteria. The goal is to provide early access to this treatment while gathering additional safety data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTPARTUM DEPRESSION are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brexanolone injection
What this could lead to
If successful, this program could provide a treatment option for women with postpartum depression who have limited alternatives.
What could go wrong
This is an expanded access program, not a controlled trial, so results may not be generalizable. Risks include infusion-related side effects and the need for careful monitoring.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.